drugset / Trial / NCT00114374

SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims

NCT00114374 ↗

Phase 3 Terminated 60 enrolled Massachusetts General Hospital
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to examine the efficacy of escitalopram compared to placebo in reducing Acute Stress Disorder (ASD) symptoms and in preventing the emergence of Post-Traumatic Stress Disorder (PTSD) in patients with medical trauma who are at risk for the development of PTSD based on the presence of ASD symptoms.

Timeline

Start
2005-06
Primary completion
—
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg —
Subject Escitalopram Small molecule 40 mg —

Indications